UB Paderborn / Katalog / Suche / in CDI

The Biodistribution and Immune Suppressive Effects of Breast Cancer-Derived Exosomes

Cancer research (Chicago, Ill.), 2016-12, Vol.76 (23), p.6816-6827

2016

Link zum Volltext

Verfügbarkeit prüfen

NLRP3 Suppresses NK Cell―Mediated Responses to Carcinogen-Induced Tumors and Metastases

Cancer research (Chicago, Ill.), 2012-11, Vol.72 (22), p.5721-5732

2012

Link zum Volltext

Verfügbarkeit prüfen

Primary Tumor Hypoxia Recruits CD11b+/Ly6Cmed/Ly6G+ Immune Suppressor Cells and Compromises NK Cell Cytotoxicity in the Premetastatic Niche

Cancer research (Chicago, Ill.), 2012-08, Vol.72 (16), p.3906-3911

2012

Link zum Volltext

Verfügbarkeit prüfen

Siah: A Promising Anticancer Target

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8), p.2400-2406

2013

Link zum Volltext

Verfügbarkeit prüfen

Vascular Normalization by Loss of Siah2 Results in Increased Chemotherapeutic Efficacy

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (7), p.1694-1704

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5546: A murine reactive version of TAK-573 (anti-CD38 attenuated IFNα fusion protein) shows immunomodulatory and antitumor activity, alone and in combination with standard-of-care agents, in IFNa-insensitive, immunocompetent murine multiple myeloma tumor models

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5546-5546

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2491: Engineering and preclinical activity of MM-201, a best-in-class TRAIL receptor agonist

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2491-2491

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3270: Mechanism of action of a novel agonist TNFR2 antibody that induces co-stimulation of T cells and promotes robust anti-tumor immunity

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3270-3270

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4846: MM-401, a novel anti-TNFR2 antibody that induces T cell co-stimulation, robust anti-tumor activity and immune memory

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4846-4846

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 555: A novel human TNFR2 antibody (MM-401) modulates T cell responses in anti-cancer immunity

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.555-555

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5008-5008

2017

Link zum Volltext

Verfügbarkeit prüfen

Voluntary Running Prevents Progressive Memory Decline and Increases Adult Hippocampal Neurogenesis and Growth Factor Expression after Whole-Brain Irradiation

Cancer research (Chicago, Ill.), 2010-11, Vol.70 (22), p.9329-9338

2010

Link zum Volltext

Verfügbarkeit prüfen

Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy

Cancer research (Chicago, Ill.), 2006-04, Vol.66 (7), p.3386-3391

2006

Link zum Volltext

Verfügbarkeit prüfen

Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non-Small Cell Lung Cancer

Cancer research (Chicago, Ill.), 2020-09, Vol.80 (17), p.3556-3567

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5895: Whole-genome characterization of lung adenocarcinomas lacking alterations in RTK/RAS/RAF/MAPK pathway

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5895-5895

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-08-20: The normal breast Active transcriptome associated with future breast cancer risk is driven by a dysregulated adipocyte microenvironment

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P3-P3-08-20

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 619: ALT-803 enhances antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by NEO-201 against human carcinoma cells

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.619-619

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5820: NF-κB signaling regulates miRNA expression in ovarian cancer

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5820-5820

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3188: Modulating UGDH expression in ovarian cancer tumor-initiating cells alters the tumor microenvironment

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3188-3188

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3781: NF-κB classical and alternative signaling differentially regulate miRNA expression in ovarian cancer

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.3781-3781

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT123: IMvoke010: Randomized Phase III study of atezolizumab as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT123-CT123

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4022: PT2385, a novel HIF-2 antagonist, combines with checkpoint inhibitor antibodies to inhibit tumor growth in preclinical models by modulating myeloid cells and enhancing T cell infiltration

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4022-4022

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4022: PT2385, a novel HIF-2α antagonist, combines with checkpoint inhibitor antibodies to inhibit tumor growth in preclinical models by modulating myeloid cells and enhancing T cell infiltration

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4022-4022

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT3-09-01: Use of Oncotype DX DCIS for disease management in a prospective DCIS registry

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.OT3-09-01-OT3-09-01

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-07-21: Breast cancer subtype and survival in a population-based cohort of patients from California

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P3-P3-07-21

2015

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

The Biodistribution and Immune Suppressive Effects of Breast Cancer-Derived Exosomes

NLRP3 Suppresses NK Cell―Mediated Responses to Carcinogen-Induced Tumors and Metastases

Primary Tumor Hypoxia Recruits CD11b+/Ly6Cmed/Ly6G+ Immune Suppressor Cells and Compromises NK Cell Cytotoxicity in the Premetastatic Niche

Siah: A Promising Anticancer Target

Vascular Normalization by Loss of Siah2 Results in Increased Chemotherapeutic Efficacy

Abstract 5546: A murine reactive version of TAK-573 (anti-CD38 attenuated IFNα fusion protein) shows immunomodulatory and antitumor activity, alone and in combination with standard-of-care agents, in IFNa-insensitive, immunocompetent murine multiple myeloma tumor models

Abstract 2491: Engineering and preclinical activity of MM-201, a best-in-class TRAIL receptor agonist

Abstract 3270: Mechanism of action of a novel agonist TNFR2 antibody that induces co-stimulation of T cells and promotes robust anti-tumor immunity

Abstract 4846: MM-401, a novel anti-TNFR2 antibody that induces T cell co-stimulation, robust anti-tumor activity and immune memory

Abstract 555: A novel human TNFR2 antibody (MM-401) modulates T cell responses in anti-cancer immunity

Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

Voluntary Running Prevents Progressive Memory Decline and Increases Adult Hippocampal Neurogenesis and Growth Factor Expression after Whole-Brain Irradiation

Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy

Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non-Small Cell Lung Cancer

Abstract 5895: Whole-genome characterization of lung adenocarcinomas lacking alterations in RTK/RAS/RAF/MAPK pathway

Abstract P3-08-20: The normal breast Active transcriptome associated with future breast cancer risk is driven by a dysregulated adipocyte microenvironment

Abstract 619: ALT-803 enhances antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by NEO-201 against human carcinoma cells

Abstract 5820: NF-κB signaling regulates miRNA expression in ovarian cancer

Abstract 3188: Modulating UGDH expression in ovarian cancer tumor-initiating cells alters the tumor microenvironment

Abstract 3781: NF-κB classical and alternative signaling differentially regulate miRNA expression in ovarian cancer

Abstract CT123: IMvoke010: Randomized Phase III study of atezolizumab as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN)

Abstract 4022: PT2385, a novel HIF-2 antagonist, combines with checkpoint inhibitor antibodies to inhibit tumor growth in preclinical models by modulating myeloid cells and enhancing T cell infiltration

Abstract 4022: PT2385, a novel HIF-2α antagonist, combines with checkpoint inhibitor antibodies to inhibit tumor growth in preclinical models by modulating myeloid cells and enhancing T cell infiltration

Abstract OT3-09-01: Use of Oncotype DX DCIS for disease management in a prospective DCIS registry

Abstract P3-07-21: Breast cancer subtype and survival in a population-based cohort of patients from California

Aktive Filter

Suchergebnisse filtern